Sachin Jain
BofA Securities, Research Division
My pleasure to kick off the next session. It’s Sachin Jain here from European team at Bank of America. My pleasure to be hosting Paul Hudson, CEO of Sanofi, we have 40 minutes. I think, Paul, perhaps some interim commentary and then we’ll get into Q&A. So with that, over to you.
Paul Hudson
CEO & Director
So it’s been an interesting year for me and for us. And while we’ve advanced the pipeline quite significantly. The only thing that’s really irritating me was the itepekimab readout with 1 positive from 1 negative putting us in a complicated situation, we can get into that, just come from the EADV, very excited about brivekimig or bispecific NHS, the amlitelimab feedback was extraordinary, and we can get into that. It’s — I know that people accused me of being optimistic, but I do enjoy immunology marketplaces, share some of the insights, I picked up, if you like it. It was great for us.
Tolebrutinib extension of PDUFA, I would rather they took longer to look at the data then made a decision with less data. So we will see how that plays out. Specifically, they will look at the GEMINI 1 and 2 data, which is good for us because you know the underlying disease, disability progression, impact with tole was almost as good as the secondary progressive population. We will see not in the FDA, but I’d rather it took longer and got to right conclusion. We’re excited about where that will go post approval.
The underlying performance is strong
#Sanofi #SANCA #Presents #Bank #America #Global #Healthcare #Conference #Transcript